HempFusion (TSX:CBD.U/FWB:800) is not standing still by any means: the CBD health and wellness specialist has just completed a pilot study using its CBD Capsules to test their effectiveness as an anti-inflammatory treatment.
The study was conducted in conjunction with the Inflammatory Markets Laboratory in Kansas and has led to the production of a white paper on the topic looking at the potential for CBD products in this area. The paper has not been published yet, but is expected very shortly, and has been co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama.
Close followers of HempFusion will know that the company is also dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.
“We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products,” said Jason Mitchell, N.D., HempFusion’s Co-Founder and Chief Executive Officer.
CBD’s role as a potential pain controller is also generating interest in research circles. A study from the European Journal of Pain, for example, shows that CBD applied to the skin can help lower pain and inflammation caused by arthritis. It can also inhibit inflammatory and neuropathic pain, which are two of the most chronic sources of pain to treat. More study in humans is still needed, however, hence it is interesting to see HempFusion products are being trialled in studies in this area.
Listen: Podcast with Jason Mitchell, CEO of HempFusion
With 94% of Americans now supporting legal access to medical cannabis, there is now a demand for further research into its properties and benefits.
“We are in the midst of an incredibly exciting time, with new discoveries occurring daily in cannabinoid science, and I am eager to see what the future holds,” said Dr Peter Grinspoon, a primary care physician in Boston who also teaches at Harvard Medical School. “However, just as we’ve learned from our experiences with CBD, we need to be patient and filter our enthusiasm through the calm lens of science.”
HempFusion recently listed in Canada and is a mature CBD health and wellness play with an impressive distribution portfolio, selling its products in around 4000 retail locations across the United States. It has coverage of all 50 US states and is starting to distribute internationally – e.g. Ireland. We expect that we will see further international distribution, especially in Europe, announced in the next six months.
HempFusion is known for its very diverse product portfolio – it has 48 SKUs including tinctures, proprietary FDA Drug Listed over-the-counter (OTC) topicals, doctor/practitioner lines and more.
With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is also a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data.